Ulcerative Colitis | Pharmacor | G7 | 2014
Last Updated 22 May 2014
Although colectomy is curative for the potentially fatal immune disease ulcerative colitis (UC), this procedure is life altering, and therefore unmet need remains for additional pharmacotherapies that more effectively treat moderate to severe disease and maintain disease remission better than existing drugs. Additional lines of tumor necrosis factor-alpha (TNF-α) inhibitor treatment in the form of SC agents and the uptake of two emerging therapies with novel mechanisms of action for patients with moderate to severe disease will drive strong growth of the UC market throughout our 2012-2022 forecast period, while innovative reformulations of current therapies will expand treatment options for patients with mild to moderate UC.
